Stock listing
Frankfurt:6HV1 Rezolute, Inc. Aktie
German listing (Frankfurt) of Rezolute, Inc. · home listing NASDAQ:RZLT
Follow Rezolute, Inc. into a list and get an email when it puts out news.
Share price · FWB:6HV1
€3.72 EUR -0.06 (-1.6%)
Close on Nov 20, 2026
- Day range
- €3.72 – €3.74 EURNov 20, 2026
- Traded on an average day
- €76 EURMedian day 0 shares · 54 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RZLT · Home | $3.92 USD | -0.33 (-7.8%) | 2,474,508 | $4.05 | $4.23 | $3.86 | $4.25 | Close on Nov 20, 2026 |
| Frankfurt:6HV1 | €3.72 EUR | -0.06 (-1.6%) | — | €3.74 | €3.74 | €3.72 | €3.78 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:6HV1 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €3.331 | +0.167 | +5.3% | €3.189 | €3.392 | €3.144 | 0 | |
| €3.164 | -0.462 | -12.7% | €3.426 | €3.433 | €3.158 | 1,000 | |
| €3.626 | +0.071 | +2.0% | €3.533 | €3.661 | €3.527 | 0 | |
| €3.555 | +0.107 | +3.1% | €3.414 | €3.562 | €3.407 | 0 | |
| €3.448 | -0.102 | -2.9% | €3.443 | €3.45 | €3.439 | 0 | |
| €3.55 | -0.197 | -5.3% | €3.579 | €3.584 | €3.504 | 0 | |
| €3.747 | +0.135 | +3.7% | €3.723 | €3.748 | €3.699 | 0 | |
| €3.612 | +0.218 | +6.4% | €3.612 | €3.612 | €3.612 | 0 | |
| €3.394 | +0.021 | +0.6% | €3.369 | €3.407 | €3.354 | 0 | |
| €3.373 | +0.114 | +3.5% | €3.373 | €3.373 | €3.373 | 0 | |
| €3.259 | -0.054 | -1.6% | €3.327 | €3.361 | €3.235 | 0 | |
| €3.313 | +0.035 | +1.1% | €3.187 | €3.346 | €3.178 | 0 | |
| €3.278 | +0.068 | +2.1% | €3.239 | €3.281 | €3.209 | 0 | |
| €3.21 | +0.061 | +1.9% | €3.221 | €3.233 | €3.207 | 0 | |
| €3.149 | -0.206 | -6.1% | €3.146 | €3.173 | €3.144 | 0 | |
| €3.355 | -0.337 | -9.1% | €3.446 | €3.471 | €3.352 | 0 | |
| €3.692 | -0.246 | -6.2% | €3.613 | €3.706 | €3.601 | 0 | |
| €3.938 | -0.28 | -6.6% | €4.061 | €4.066 | €3.935 | 0 | |
| €4.218 | -0.02 | -0.5% | €4.261 | €4.303 | €4.212 | 0 | |
| €4.238 | +0.212 | +5.3% | €4.281 | €4.30 | €4.21 | 0 | |
| €4.026 | +0.208 | +5.4% | €4.058 | €4.058 | €3.977 | 0 | |
| €3.818 | -0.014 | -0.4% | €3.838 | €3.848 | €3.788 | 0 | |
| €3.832 | +0.066 | +1.8% | €3.74 | €3.869 | €3.737 | 0 | |
| €3.766 | +0.16 | +4.4% | €3.889 | €3.907 | €3.763 | 0 | |
| €3.606 | -0.013 | -0.4% | €3.503 | €3.612 | €3.489 | 0 | |
| €3.619 | -0.069 | -1.9% | €3.561 | €3.648 | €3.554 | 0 | |
| €3.688 | +0.06 | +1.7% | €3.634 | €3.691 | €3.541 | 30 | |
| €3.628 | -0.008 | -0.2% | €3.574 | €3.632 | €3.526 | 0 | |
| €3.636 | +0.296 | +8.9% | €3.634 | €3.652 | €3.63 | 0 | |
| €3.34 | -0.05 | -1.5% | €3.36 | €3.371 | €3.313 | 0 | |
| €3.39 | -0.041 | -1.2% | €3.39 | €3.39 | €3.39 | 0 | |
| €3.431 | -0.013 | -0.4% | €3.431 | €3.431 | €3.431 | 0 | |
| €3.444 | +0.095 | +2.8% | €3.444 | €3.444 | €3.444 | 0 | |
| €3.349 | +0.058 | +1.8% | €3.349 | €3.349 | €3.349 | 0 | |
| €3.291 | -0.061 | -1.8% | €3.291 | €3.291 | €3.291 | 0 | |
| €3.352 | -0.081 | -2.4% | €3.399 | €3.416 | €3.337 | 0 | |
| €3.433 | -0.125 | -3.5% | €3.387 | €3.436 | €3.379 | 0 | |
| €3.558 | +0.01 | +0.3% | €3.545 | €3.563 | €3.512 | 0 | |
| €3.548 | +0.065 | +1.9% | €3.594 | €3.596 | €3.525 | 0 | |
| €3.483 | -0.05 | -1.4% | €3.534 | €3.581 | €3.466 | 0 | |
| €3.533 | +0.10 | +2.9% | €3.545 | €3.59 | €3.533 | 0 | |
| €3.433 | -0.28 | -7.5% | €3.442 | €3.445 | €3.419 | 0 | |
| €3.713 | -0.042 | -1.1% | €3.741 | €3.751 | €3.713 | 0 | |
| €3.755 | -0.06 | -1.6% | €3.744 | €3.789 | €3.732 | 0 | |
| €3.815 | +0.035 | +0.9% | €3.815 | €3.815 | €3.815 | 0 | |
| €3.78 | -0.048 | -1.3% | €3.799 | €3.819 | €3.774 | 0 | |
| €3.828 | +0.02 | +0.5% | €3.851 | €3.864 | €3.827 | 0 | |
| €3.808 | -0.125 | -3.2% | €3.796 | €3.864 | €3.771 | 0 | |
| €3.933 | +0.003 | +0.1% | €3.961 | €3.993 | €3.908 | 0 | |
| €3.93 | -0.163 | -4.0% | €3.891 | €3.934 | €3.874 | 0 | |
| €4.093 | -0.143 | -3.4% | €4.159 | €4.186 | €4.09 | 0 | |
| €4.236 | +0.044 | +1.0% | €4.245 | €4.263 | €4.22 | 0 | |
| €4.192 | -0.057 | -1.3% | €4.212 | €4.22 | €4.154 | 250 | |
| €4.249 | +0.203 | +5.0% | €4.239 | €4.252 | €4.224 | 0 | |
| €4.046 | +0.085 | +2.1% | €4.263 | €4.272 | €4.013 | 0 | |
| €3.961 | +0.064 | +1.6% | €3.934 | €3.965 | €3.867 | 0 | |
| €3.897 | -0.098 | -2.5% | €3.907 | €3.919 | €3.894 | 0 |
- Ticker
- Frankfurt:6HV1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 13, 2026
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 35 slides
Latest news
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Nov 5, 2026
Closed €3.33 (+5.3%) on Nov 6, 2026
Rezolute to Participate in Upcoming Investor Conferences
Nov 2, 2026
Closed €3.45 (-2.9%) on Nov 2, 2026
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Oct 14, 2026
Closed €3.69 (-6.2%) on Oct 15, 2026
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Oct 5, 2026
Closed €3.61 (-0.4%) on Oct 5, 2026
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Sep 24, 2026
Closed €3.39 (-1.2%) on Sep 25, 2026
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Sep 9, 2026
Closed €3.71 (-1.1%) on Sep 9, 2026
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Jun 17, 2026
Closed €3.82 (+5.0%) on Jun 17, 2026
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Jun 4, 2026
Closed €3.79 (+2.4%) on Jun 4, 2026
Rezolute, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 124 in all · newest Nov 13, 2026 · oldest 2019
- Decks
- 29 decks · latest November 2026
Where Rezolute, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RZLT · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2QEWP | LS Exchange | Germany | EUR |
| BOATS:RZLT | BOATS | United States | USD |
| Lang & Schwarz:A2QEWP | Lang & Schwarz | Germany | EUR |
| Dusseldorf:6HV1 | Dusseldorf | Germany | EUR |
| Frankfurt:6HV1 · This page | Frankfurt | Germany | EUR |
| Munich:6HV1 | Munich | Germany | EUR |
| Stuttgart:6HV1 | Stuttgart | Germany | EUR |
| Tradegate:6HV1 | Tradegate | Germany | EUR |
Valuation
Price/book 4.4× against a median of 4.1×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $289.9M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.28
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rezolute, Inc. · NASDAQ:RZLT | US$379.2M | US$289.9M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.28 |
| Mezzion Pharma Co., Ltd. · KRX:140410 | US$391.0M | US$360.8M | n/a | 57.3× | n/a | 13.4× | −325.0% | 0.0× | n/a |
| Avalo Therapeutics, Inc. · NASDAQ:AVTX | US$390.9M | −US$1.93M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.25 |
| Qurient Co., Ltd. · KRX:115180 | US$388.5M | US$372.4M | n/a | 70.5× | n/a | 30.2× | −543.0% | 0.8× | n/a |
| Beijing Luzhu Biotechnology Co., Ltd. Class H · HKEX:2480 | US$388.2M | US$369.1M | n/a | n/a | n/a | 4.3× | n/a | 0.4× | n/a |
| Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378 | US$387.5M | US$316.0M | n/a | n/a | n/a | 4.1× | n/a | 0.1× | n/a |
| Opus Genetics, Inc. · NASDAQ:IRD | US$385.7M | US$332.3M | n/a | 42.0× | n/a | 10.0× | n/a | 0.9× | 1.01 |
| Eupraxia Pharmaceuticals, Inc. · TSX:EPRX | US$384.3M | US$252.7M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.53 |
| Hinova Pharmaceuticals, Inc. Class A · SSE:688302 | US$381.1M | US$285.9M | n/a | 23.0× | n/a | 2.6× | −167.3% | 0.1× | n/a |
| Phathom Pharmaceuticals, Inc. · NASDAQ:PHAT | US$378.8M | US$359.8M | n/a | 1.3× | n/a | n/a | −30.2% | n/a | 1.08 |
| Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509 | US$370.7M | US$380.5M | 4.5× | 2.5× | 4.2× | 2.9× | 53.3% | 0.8× | n/a |
| Median of the others | US$386.6M | US$346.1M | 4.5× | 32.5× | 4.2× | 4.1× | −167.3% | 0.1× | 1.17 |
Forecasts
9 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.80 USD · Analysts' mean
- EPS, year to Jun 2027
- -0.65 · 8 analysts
- Revenue, year to Jun 2027
- 2.09M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Nevan Charles Elam | Chief Executive Officer & Founder |
| Daron Evans | Chief Financial and Business Officer |
| Michael R. Deperro | Senior Vice President & Head of Operations |
| Brian Roberts | Chief Medical Officer |
| Erik Harris | Board Member |
| Nerissa Kreher | Board Member |
| Sunil Karnawat | Chief Commercial Officer |
| Susan Stewart | Chief Regulatory Officer |
| Vlad Hogenhuis | Board Member |
Board
| Director | Role |
|---|---|
| Erik Harris | Board Member |
| Gil Labrucherie | Board Member |
| Nerissa Kreher | Board Member |
| Nevan Charles Elam | Chief Executive Officer & Founder |
| Philippe Fauchet | Board Member |
| Vlad Hogenhuis | Board Member |
| Young-Jin Kim | Board Member |
Events
- Next results
- Feb 11, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q1 2027 | Nov 5, 2026 · After close | +6.6% |
| Q4 2026 | Sep 24, 2026 · After close | −1.0% |
| Q3 2026 | May 13, 2026 | +3.0% |
| Q2 2026 | Feb 12, 2026 · After close | +5.8% |
| Q1 2026 | Nov 6, 2025 · After close | +12.1% |
| Q4 2025 | Sep 17, 2025 | +6.2% |
| Q3 2025 | May 13, 2025 · After close | −4.9% |
| Q2 2025 | Feb 12, 2025 · After close | −1.0% |
| Q1 2025 | Nov 7, 2024 · After close | −2.5% |
| Q4 2024 | Sep 19, 2024 · After close | +5.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2024 | May 15, 2024 · After close | −3.4% |
| Q2 2024 | Feb 13, 2024 · After close | +13.8% |
| Q1 2024 | Nov 13, 2023 · After close | −7.4% |
| Q4 2023 | Sep 14, 2023 · After close | 0.0% |
| Q3 2023 | May 11, 2023 · After close | +2.0% |
| Q2 2023 | Feb 10, 2023 · After close | −3.2% |
| Q1 2023 | Nov 9, 2022 · After close | 0.0% |
| Q4 2022 | Sep 15, 2022 · After close | +0.4% |
| Q3 2022 | May 12, 2022 · After close | +6.2% |
| Q2 2022 | Feb 9, 2022 · After close | −0.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 35 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 34 slides | October 2026 |
| Investor Presentation (August 2026) | Investor deck | 31 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 31 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 38 slides | May 2026 |
| Investor Presentation (March 2026) | Investor deck | 35 slides | March 2026 |
| Investor Presentation (February 2026) | Investor deck | 34 slides | February 2026 |
| Investor Presentation (January 2026) | Investor deck | 34 slides | Jan 7, 2026 |
| Investor Presentation (January 2026) | Investor deck | 35 slides | January 2026 |
| Investor Day (November 2025) | Investor day | 40 slides | Nov 12, 2025 |
All 29 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$100M · US$3.87 a share · Morgan Stanley +6 Dealers: Morgan Stanley (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), H.C. Wainwright & Co., Jones, Maxim Group LLC, Lake Street Capital Markets, LLC Buyers: Frazier Life Sciences Use of proceeds: Ersodetug commercialization preparation, working capital and general corporate purposes | Nov 13, 2026 |
| Public offering of common stock and pre-funded warrants Closed: US$96.9M raised · US$3.25 a share · Guggenheim Securities +6 Dealers: Guggenheim Securities (lead), BTIG (co-lead), H.C. Wainwright & Co. (co-lead), Jones (co-lead), Craig-Hallum, Maxim Group LLC, WG Partners LLP Buyers: Federated Hermes Kaufmann Funds; Blackstone Multi-Asset Investing; Great Point Partners, LLC; Marshall Wace; Woodline Partners LP; Nantahala Capital; Squadron Capital Management Use of proceeds: Research and development, general corporate expenses and working capital needs | Apr 25, 2025 |
| Private placement of shares of common stock Announced: up to US$4.2M | Apr 25, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 31.0K | 31.0K | 36.0K | 382.0K | 256.0K | 13.0K | 18.0K | 48.0K | 0 | 12.6M |
| Gross profit | -31.0K | -31.0K | -36.0K | -382.0K | -256.0K | -13.0K | -18.0K | -48.0K | 0 | -12.6M |
| Research and development | 53.8M | 61.5M | 55.7M | 43.8M | 32.5M | 15.0M | 14.4M | 19.1M | 17.3M | 12.1M |
| Selling, general and administrative | 29.2M | 18.4M | 14.7M | 12.2M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M |
| Operating income | -83.0M | -79.9M | -70.4M | -56.0M | -41.8M | -22.9M | -20.5M | -25.9M | -28.7M | -20.3M |
| Depreciation and amortization | 31.0K | 31.0K | 36.0K | 30.0K | 13.0K | 13.0K | 18.0K | 49.0K | 1.07M | 1.11M |
| EBITDA | -82.9M | -79.9M | -70.4M | -56.0M | -41.8M | -22.9M | -20.5M | -25.9M | -27.7M | -19.2M |
| Interest expense | 919.0K | 1.81M | 375.0K | 0 | 4.96M | 689.0K | 1.59K | |||
| Income before tax | -77.6M | -74.4M | -68.5M | -51.8M | -41.1M | -20.9M | -20.3M | -30.4M | -29.9M | -20.3M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -77.6M | -74.4M | -68.5M | -51.8M | -41.1M | -20.9M | -20.3M | -30.4M | -29.9M | -20.3M |
| Earnings per share, basic | -0.75 | -0.98 | -1.33 | -1.01 | -2.26 | -2.72 | -3.54 | -18.41 | -0.54 | -0.57 |
| Earnings per share, diluted | -0.75 | -0.98 | -1.33 | -1.01 | -2.32 | -2.72 | -3.54 | -18.41 | -0.54 | -0.57 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.6M | 94.1M | 70.4M | 16.0M | 150.4M | 41.0M | 77.4M | 37.6M | 1.65M | 4.49M |
| Short-term investments | 97.2M | 73.8M | 56.5M | 85.9M | 0 | |||||
| Receivables | 500.0K | 700.0K | ||||||||
| Current assets | 110.5M | 171.1M | 128.7M | 104.9M | 152.1M | 42.0M | 10.5M | 12.1M | 2.01M | 4.93M |
| Property, plant and equipment | 41.0K | 72.0K | 103.0K | 139.0K | 16.0K | 29.0K | 33.0K | 44.0K | 368.0K | 5.33M |
| Total assets | 112.8M | 175.5M | 132.7M | 123.7M | 152.4M | 42.6M | 11.0M | 12.3M | 2.50M | 10.6M |
| Accounts payable | 5.03M | 5.81M | 4.90M | 3.27M | 1.13M | 1.03M | 893.0K | 563.0K | 1.71M | 926.0K |
| Current liabilities | 11.4M | 11.9M | 9.61M | 5.20M | 2.46M | 1.97M | 3.23M | 8.38M | 6.25M | 1.77M |
| Long-term debt | 407.0K | 14.0M | ||||||||
| Total debt | 934.0K | 1.61M | 2.23M | 2.48M | 515.0K | 14.0M | 0 | 0 | 3.42M | 10.0K |
| Total liabilities | 12.2M | 13.4M | 11.7M | 7.55M | 2.95M | 16.5M | 3.60M | 10.5M | 6.46M | 2.10M |
| Shareholders' equity | 100.7M | 162.1M | 121.0M | 116.2M | 149.5M | 26.1M | 7.37M | 1.75M | -3.96M | 8.53M |
| Shares outstanding | 96.4M | 87.0M | 53.2M | 36.8M | 33.6M | 8.35M | 5.87M | 4.21M | 62.2K | 49.2M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -64.6M | -69.1M | -57.4M | -44.5M | -39.6M | -20.4M | -24.2M | -15.3M | -14.1M | -13.3M |
| Capital spending | 0 | 0 | 0 | -153.0K | -153.0K | -153.0K | 0 | -47.0K | -6.00K | -407.9K |
| Free cash flow | -64.6M | -69.1M | -57.4M | -44.6M | -39.6M | -20.4M | -24.2M | -15.4M | -14.1M | -13.7M |
| Cash from investing | -21.1M | -14.5M | 48.7M | -101.5M | -101.5M | 0 | 0 | 231.0K | 1.73M | -195.4K |
| Cash from financing | 2.24M | 107.3M | 63.0M | 11.6M | 149.0M | 51.5M | 22.6M | 25.0M | 9.54M | 13.9M |
| Share buybacks | -3.00K | 179.8M | 14.6M | |||||||
| Change in cash | -83.5M | 23.7M | 54.4M | -134.4M | 109.4M | 31.1M | -1.62M | 9.93M | -2.84M | 424.5K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 19, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Nov 16, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| FWP · Free writing prospectus | Nov 13, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Nov 13, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 12, 2026 | Other filings | SEC |
| S-3 · Registration statement | Nov 5, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Oct 21, 2026 | Meeting notice | SEC |
| DRS · Draft registration statement | Oct 15, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Oct 7, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 5, 2026 | Current report | SEC |
| 10-K · Annual report | Sep 24, 2026 | Annual report | SEC |
| 8-K · Current report | Sep 24, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 24, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 18, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| S-3ASR · Registration statement | Dec 5, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 21, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 21, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 17, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 7, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 22, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Sep 17, 2025 | Annual report | SEC |
| 8-K · Current report | Sep 17, 2025 | Results | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Aug 11, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Aug 1, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 24, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 18, 2025 | Current report | SEC |
| S-3 · Registration statement | Jul 17, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jun 13, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 13, 2025 | Financing | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 8-K · Current report | Apr 23, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Apr 23, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Apr 23, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 28, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 12, 2025 | Results | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| 8-K · Current report | Jan 14, 2025 | Current report | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Dec 30, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 10, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Oct 21, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 21, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 10, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 10-K · Annual report | Sep 19, 2024 | Annual report | SEC |
| 8-K · Current report | Sep 19, 2024 | Results | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 13, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Aug 9, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 9, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 5, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 8-K · Current report | Jun 28, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 14, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 14, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 13, 2024 | Offer document | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 8-K · Current report | May 17, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 8-K · Current report | Apr 25, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 14, 2024 | Material contract | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Mar 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 22, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Feb 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
This page holds 200 of 768 filings. Open Filings
Cap table
Built by 6ix from Rezolute, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 96,722,333
- Fully diluted
- 96,722,333
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 96,722,333 | Sep 21, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 21, 2026 | 96,722,333 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Erik Harris Other companies: Ultragenyx Pharmaceutical Inc. (EVP & Chief Commercial Officer · Since at least Jun 11, 2019); Inozyme Pharma Inc (Director · Oct 3, 2024 – Oct 3, 2024 · Past); Denali Therapeutics Inc. (Director · Feb 3, 2022 – May 31, 2024 · Past) | Board Member · Since at least Mar 25, 2025 |
| Gil Labrucherie Other companies: Septerna, Inc. (Chief Financial Officer · Since at least Jan 6, 2025); Acelyrin, Inc. (CFO and CBO · Oct 4, 2023 – Aug 31, 2024 · Past) | Director · Since at least Jan 23, 2024 |
| Nerissa Kreher Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Jun 30, 2026); Entrada Therapeutics, Inc. (Chief Medical Officer · Jul 1, 2022 – Sep 1, 2023 · Past) | Board Member · Since at least Jun 23, 2022 |
| Daron Evans Other companies: Nephros, Inc. (CEO of Specialty Renal Product · May 24, 2021 – May 24, 2021 · Past) | CFO · Since at least Jan 22, 2024 |
| Morgan Fields Other companies: Arq, Inc. (Chief Accounting Officer · Apr 1, 2021 – Aug 17, 2023 · Past) | Chief Accounting Officer · Jul 18, 2014 – Oct 31, 2016 · Past |
| Nevan Charles Elam Other companies: Savara, Inc. (Director · Since at least Dec 2, 2025) | Chief Executive Officer & Founder · Since at least Jun 10, 2025 |
| Barry Michael Sherman | Director · Jul 18, 2014 – Oct 31, 2016 · Past |
| Brian Roberts | Chief Medical Officer · Since at least Oct 23, 2020 |
| Gil Labrucherie | Board Member · Since at least Nov 4, 2026 |
| Michael R. Deperro | Senior Vice President & Head of Operations · Since at least Nov 4, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Philippe Fauchet | Board Member · Since at least Nov 5, 2026 |
| Sankaram Mantripragada | Chief Scientific Officer · Jan 31, 2013 – Jul 31, 2019 · Past |
| Sunil Karnawat | Chief Commercial Officer · Since at least Aug 20, 2025 |
| Susan Stewart | Chief Regulatory Officer · Since at least Dec 3, 2024 |
| Vlad Hogenhuis | Board Member · Since at least Nov 4, 2026 |
| Young Chul Sung | Director · Feb 11, 2019 – Feb 11, 2019 · Past |
| Young-Jin Kim | Board Member · Since at least Feb 11, 2019 |
Log in to ask 6ix AI your own questions about Rezolute, Inc.